Discussion of the mechanism of Qixuan Yijianing in the treatment of Graves disease based on network pharmacology and animal experiments
GAO Changjiu1 DING Song1 LU Fang2 LIU Changfeng2 YU Donghua2 LIU Shumin2
1.Graduate School, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Institute of Chinese Medicine, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China
Abstract：Objective To explore the mechanism of Qixuan Yijianing in the treatment of Graves disease (GD) based on network pharmacology and animal experiments. Methods The active constituents and targets of Qixuan Yijianing were detected by traditional Chinese medicine systems pharmacology database and analysis platform, and chemical database, and GD related targets were detected from Genecards, online human Mendelian genetic database, etc. The common targets of drugs and diseases were introduced into STRING platform to construct protein-protein interaction (PPI) network and screen core targets. Cytoscape 3.8.2 software was used to map the drug-active ingredient-target network and screen core components. The core target was enriched by Metascape platform. Forty 6-week-old female BALB/c mice with SPF grade and body weight of (20±2) g were selected, ten of which were set as normal control group, and the remaining 30 were immunized with recombinant adenovirus Ad-TSHR-289 for three times to construct GD model. The mice that modeled successfully were divided into GD model group, Methimazole group, and Qixuan Yijianing group by random number table method, with eight mice in each group. Qixuan Yijianing group was intragastric administration of Qixuan Yijianing 50 g/kg, Methimazole group was intragastric administration of Methimazole Tablets 3.75 mg/kg, normal control group and GD model group were intragastric administration of drinking water of the same volume, once a day. After four weeks of continuous administration, serum vascular endothelial growth factor (VEGF) content was detected by enzyme-linked immunosorbent assay. The expression of platelet endothelial cell adhesion molecule-1 (PECAM-1) in thyroid tissues of the four groups was detected by immunohistochemistry. Results A total of 63 active ingredients with 281 targets and 1 489 targets of GD were obtained. There were 124 targets of drugs and diseases. PPI obtained 21 core targets of signal transduction and transcription activator 3, serine/threonine protein kinase 1, VEGFA, etc. Eighteen core components including luteolin, kaempferol, quercetin, ursolic acid, and β-sitosterol were obtained by drug-target analysis. 954 items of inflammatory response, angiogenesis, and vascular morphogenesis were obtained GO by analysis, and 92 pathways including MAPK, PI3K/AKT, and VEGF were obtained by KEGG analysis. Animal experiments showed that the expression levels of serum VEGF and thyroid PECAM-1 in GD model group were higher than those in normal control group, and those in Qixuan Yijianing group were lower than those in GD model group, the differences were highly statistically significant (P＜0.01). Conclusion Qixuan Yijianing is able to treat GD by regulating MAPK, PI3K/AKT, VEGF, and other signaling pathways to inhibit angiogenesis.
高长久1 丁崧1 卢芳2 柳长凤2 于栋华2 刘树民2. 基于网络药理学结合动物实验探究芪玄抑甲宁治疗格雷夫斯病的作用机制[J]. 中国医药导报, 2023, 20(3): 9-14.
GAO Changjiu1 DING Song1 LU Fang2 LIU Changfeng2 YU Donghua2 LIU Shumin2. Discussion of the mechanism of Qixuan Yijianing in the treatment of Graves disease based on network pharmacology and animal experiments. 中国医药导报, 2023, 20(3): 9-14.
[1] Fallahi P，Ferrari SM，Elia G，et al. Cytokines as Targets of Novel Therapies for Graves’Ophthalmopathy [J]. Front Endocrinol（Lausanne），2021，6（5）：144-151.
[2] Subekti I，Pramono LA. Current Diagnosis and Management of Graves’Disease [J]. Acta Med Indones，2018，50（2）：177-182.
[3] Gonzalez-Aguilera B，Betea D，Lutteri L，et al. Conversion to Graves disease from Hashimoto thyroiditis：a study of 24 patients [J]. Arch Endocrinol Metab，2018，62（6）：609-614.
[4] 汤阳.化痰散结法干预Graves病小鼠免疫耐受及其调控失常的作用机制研究[D].北京：中国中医科学院，2019.
[5] 岳仁宋.甲状腺疾病病证结合治疗学[M].成都：四川科学技术出版社，2015：170.
[6] 刘树民，甄喆，王可心，等.芪玄抑甲宁治疗甲亢的主要药效学研究[J].中医药学报，2017，45（5）：48-51.
[7] 刘树民，甄喆，李健英，等.芪玄抑甲宁对甲亢大鼠的Th17细胞相关因子的调控影响[J].中药药理与临床，2017， 33（1）：144-148.
[8] 刘树民，甄喆，王可心，等.芪玄抑甲宁对Graves病模型药效学研究[J].辽宁中医药大学学报，2018，20（6）：5-7.
[9] 柳长凤，苗晶囡，邱军强，等.星点设计-响应面法优选芪玄抑甲宁的提取工艺[J].中医药学报，2013，41（3）：43-47.
[10] Li J，Zhao P，Li Y，et al. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease [J]. Sci Rep，2015，15（1）：52-58.
[11] 柏力萄.基于AMPK-mTOR信号通路探讨甲亢宁胶囊干预Graves病自噬与凋亡作用机制研究[D].北京：中国中医科学院，2019.
[12] 冒婧敬，相萍萍，刘超.Graves病动物模型构建的研究进展[J].实用临床医药杂志，2021，25（9）：113-117.
[13] 吴超，王彩星，韩瑜娇.连翘苷对肛周脓肿大鼠创面血管新生的促进作用[J].中国皮肤性病学杂志，2020，34（12）：1435-1442.
[14] Luo TT，Lu Y，Yan SK，et al. Network Pharmacology in Research of Chinese Medicine Formula：Methodology，Application and Prospective [J]. Chin J Integr Med，2020，26（1）：72-80.
[15] Lanzolla G，Marcocci C，Marinò M. Oxidative Stress in Graves Disease and Graves Orbitopathy [J]. Eur Thyroid J，2020,9（1）：40-50.
[16] Jang JY，Choi SY，Park I，et al. VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis [J]. EMBO Mol Med，2017，9（6）：750-769.
[17] Wang Z，Dabrosin C，Yin X，et al. Broad targeting of angiogenesis for cancer prevention and therapy [J]. Semin Cancer Biol，2015，35（8）：224-243.
[18] Kim GD. Kaempferol Inhibits Angiogenesis by Suppressing HIF-1α and VEGFR2 Activation via ERK/p38 MAPK and PI3K/Akt/mTOR Signaling Pathways in Endothelial Cells [J]. Prev Nutr Food Sci，2017，22（4）：320-326.
[19] Chin HK，Horng CT，Liu YS，et al. Kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT，MEK and ERK pathways in VEGF- stimulated human umbilical vein endothelial cells [J]. Oncol Rep，2018,39（5）：2351-2357.
[20] Marrero AD，Quesada AR，Martínez-Poveda B，et al. Antiangiogenic Phytochemicals Constituent of Diet as Promising Candidates for Chemoprevention of Cancer [J]. Antioxidants（Basel），2022，11（2）：302-308.
[21] George JK，Luigi B，Lazlo H，et al. 2018 European thyroid association guideline for the Management of Graves’Hyperthyroidism [J]. Eur Thyroid J，2018,7（4）：167-182.
[22] 陈丽梅，夏淑芳，乐国伟.槲皮素对高脂膳食小鼠肝脏甲状腺激素作用的影响[J].营养学报，2019，41（5）：482- 488，493.
[23] 夏淑芳.高脂诱导的氧化应激对甲状腺激素稳态的影响及槲皮素的调节作用[D].无锡：江南大学，2015.
[24] Habza-Kowalska E，Gawlik-Dziki U，Dziki D. Mechanism of Action and Interactions between Thyroid Peroxidase and Lipoxygenase Inhibitors Derived from Plant Sources [J]. Biomolecules，2019，9（11）：663-669.
[25] Ibrahim RYM，Saber AA，Hammad HBI. The possible role of the seaweed Ulva fasciata on ameliorating hyperthyroidism-associated heart inflammations in a rat model [J]. Environ Sci Pollut Res Int，2021，28（6）：6830-6842.
京公网安备 11010502046598号